Polymorphisms of factor V, factor VII, and fibrinogen genes: Relevance to severity of coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 2, 1997, Pages 246-251

  Wang, X L ^a   Wang, J ^a   McCredie, R M ^a   Wilcken, D E L ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE HENRY HOSPITAL   (Australia)

Author keywords

coronary artery disease; factor V mutations; factor VII; fibrinogen

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN;

ADULT; ARTICLE; AUSTRALIA; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN METABOLISM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031029434     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.2.246     Document Type: Article

References (28)

1. Salomaa V, Rasi V, Pekkanen J, Vahtera E, Jauhiainen M, Vartiainen E, Myllyla G, Ehnholm C. Haemostatic factors and prevalent coronary heart disease: the FINRISK Haemostasis Study. Eur Heart J. 1994;15:1293-1299.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabati RR, North RR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
3. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83:836-844.
4. Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet. 1992;339:693-696.
5. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
6. De Boever E, De Bacquer D, Braeckman L, Baele G, Rosseneu M, De Backer G. Relation of fibrinogen to lifestyles and to cardiovascular risk factors in a working population. Int J Epidemiol. 1995;24:915-921.
7. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Tliromb Vasc Biol. 1995;15:1263-1268.
8. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb. 1993;13:1829-1836.
9. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
10. Eliasson M, Asplund K, Evrin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin: the Northern Sweden MONICA Study. Atherosclerosis. 1995;113:41-53.
11. Thomas AE, Green FR, Lamlum H, Humphries-SB. The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers. J Med Genet. 1995;32:585-589.
12. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost. 1991;65:487-490.
13. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb. 1991;11:540-546.
14. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baronchni C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol. 1996;16:72-76.
15. Takamiya O. Genetic polymorphism (Arg353→Gln) in coagulation factor VII gene and factor VII levels (coagulant activity, antigen and binding ability to tissue factor) in 101 healthy Japanese. Scand J Clin Lab Invest. 1995;55:211-215.
16. Silveira A, Green F, Karpe F, Blomback M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost. 1994;72:734-739.
17. Humphries SE. Genetic regulation of fibrinogen. Eur Heart J. 1995;16(suppl A):16-20. Review.
18. Humphries SE, Ye S, Talmud P, Bara L, Wilhelmsen L, Tiret L. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe: evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol. 1995;15:96-104.
19. Connor JM, Fowkes FGR, Wood J, Smith FB, Donnan PT, Lowe GDO. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet. 1992;29:480-482.
20. Scarabin P-Y, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: the ECTIM study. Arterioscler Thromb. 1993;13:886-891.
21. Folsom AR, Qamhieh HT, Flack JM, Hilner JE, Liu K, Howard BV, Tracy RP, CARDIA Study. Plasma fibrinogen: levels and correlates in young adults. Am J Epidemiol. 1993;138:1023-1035.
22. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reltsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
23. 506 of factor V. Lancet. 1994;343:1535-1536.
24. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538.
25. Marz W, Seydewitz H, Winkelamnn B, Chen M, Nauck M. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet. 1995;345:526-527.
26. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistance. Lancet. 1995;345:321.
27. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis. 1989;9(suppl I):I19-I32.
28. Wang XL, McCredie RM, Wilcken DEL. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol. 1995;15:1030-1034.